Lamassu Pets

Man’s best friend may soon benefit from a groundbreaking new treatment being developed for humans, thanks to a new partnership between Lamassu Biotech and The Ohio State University.

Together, they are advancing the development of RABI-767, a novel therapeutic targeting acute pancreatitis—a life-threatening condition that currently has no effective treatments in either human or veterinary medicine. The biotech firm’s new veterinary division, Lamassu Pets, and Ohio State are slated to begin trials on dogs in the near future.

Acute pancreatitis leads to over 330,000 hospital admissions per year for humans in the United States and also affects nearly 1.8 million dogs.

Given the significant parallels in acute pancreatitis and lack of effective treatments in both dogs and humans, knowledge gained in the effective management of the disease in dogs can ultimately benefit humans, and vice versa. This new partnership will drive research aimed at bridging the gap between human and veterinary medicine, optimizing treatment strategies for both.